【摘要】 目的　探讨罗格列酮 (rosiglitazone,RSG)联合胰岛素治疗单用胰岛素控制不佳的肥胖 2型糖尿病 (2 DM)患者疗效及安全性。方法　对单用胰岛素治疗不满意的 2 DM患者糖化血红蛋白 (HbA1C) >7 5 % ,且体重指数 (BMI)≥ 2 5 ,肝功能ALT <2 5倍正常上限为治疗对象 ,在原治疗基础上加用RSG(每天 4mg)治疗 8周。结果　RSG 4mg/d显著地改善血糖 ,胰岛素剂量在治疗第 4周和第 8周平均分别减少 7 7%和 14 % ,在治疗第 8周HbA1C从基线平均下降 1 4 % ,无不良事件发生。结论　在单用胰岛素控制不佳的肥胖 2 DM患者中加用RSG治疗可显著改善血糖 ,并且耐受性良好。更多还原

【Abstract】 Objective To probe into the effect and safety of rosiglitazone combination with insulin to treat obese type 2 diabetics with poor glycemic control by insulin alone.Methods Rosiglitazone(4mg/d) was added to 30 obese type 2 diabetics with poor glycemic control by insulin alone for 4 week observation.Results Rosiglitazone improved obviously the blood sugar control,meanwhile insulin dosage used was reduced gradually by 7.7% at the 4th week and 14% at the 8th week.After 8 weeks of rosiglitazone added,HbA1c reduced by 1.4% without any side effects.Conclusion Adding rosiglitazone can significantly improve blood glucose control of who fails to gain a good blood glucose control by insulin only in obese type 2 diabetics without obvious side effects.更多还原